In the present study, we developed a risk for recurrence score (RRS), based on mRNA expression of two proliferation markers (RACGAP1 and TOP2A), in high-risk early breast cancer patients and evaluated its ability to predict risk for relapse and death. This evidence concerns the gene RACGAP1 and breast cancer.